The sample weights and strata derived by MEPS were used to allow the surveyed cohort to represent civilian, non-institutionalized US population. Those with an ICD-9 code for kidney stone occurrence and received an opioid Rx during the index 6-month period were included in the analysis. Patients characteristics were assessed for association with repeat opioid prescriptions within 6 months and opioid use for greater than 1 year.
INTRODUCTION AND OBJECTIVES:
The rise in opioid related deaths and addiction has been linked to physician prescribing. Opioids are commonly prescribed to patients with renal colic due to nephrolithiasis. The aim of this study is to describe the relationship between nephrolithiasis and opioid use in the United States.
METHODS: We performed an analysis of data from the National Health and Nutrition Examination Survey (NHANES), a periodic survey conducted by the Centers for Disease Control and Prevention, to monitor trends in the civilian population of the United States. Questions about a history of nephrolithiasis and medication use in the last 30 days were included in the Continuous NHANES surveys from 2007 to 2014. A total of 23,482 subjects over the age of twenty were surveyed, 382 (1.2%) were missing data for one or more variables and were excluded from the analysis.Multivariable logistic regression was used to evaluate the independent association between medical conditions and narcotic use. Covariates were included in the model a-priori, independent of univariate p-values, for the association between medical conditions and narcotic use. All p-values are two-sided with statistical significance evaluated at the 0.05 alpha level.
RESULTS: We found that among 23,100 subjects, current opioid use was significantly greater among those who reported a history of kidney stones at 10.9% (95% confidence interval (CI) 9.1% to 12.9%), as compared to 6.1% (95% CI 5.4% to 6.8%) of those who did not report a history of stones. The prevalence of opioid use increased with the number of kidney stones passed, reaching 13.7% (95% CI 11.1% to 16.9%) in subjects who had passed two or more stones, p<0.001. On multivariable logistic regression analysis adjusting for age, gender, smoking status, number of healthcare visits in the past year, and comorbid conditions, nephrolithiasis was independently associated with opioid-based medication use, OR 1.27 (95% CI 1.07 to 1.49), p[0.006.
CONCLUSIONS: The association between a history of kidney stones and narcotic use suggests that nephrolithiasis may be a risk factor for long-term opioid use, and that altering pain management strategies in this population may be beneficial.
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MP12-09 STENT RELATED DISCOMFORT-DOES ADDING MIRABGERON TO ANTI CHOLINERGIC REGIMES HELP?
Maniyur Raghavendran*, Keyur Patel, Milan Joshi, Mysore, India INTRODUCTION AND OBJECTIVES: Stent related symptom is one of the most discomforting situation after performance of ureteroscopic lithotripsy. It has resulted in indiscriminate use of opioids as a means of pain relief. Prelimnary studies showed promising results with Solifenacin alone in enhanced dose. In order to further pain relief, combination of solifenacin with either alpha blocker Tamsulosin or with Mirabgeron was thought of. This study is an effort in this direction whether combination is better than Solifenacin alone. Also stent causes severe lower urinary tract symptoms, which are equally troublesome but neglected when compared to pain. So, we wanted to see whether combination treatment is effective in relieving this discomforting symptom.
METHODS: 150 patients undergoing Ureteroscopic lithotripsy were included for the study. 50 patients were randomly allocated to recieve Solifenacin 20 mg/ day, Solifenacin with Tamsulosin 0.4 mg,and Solifenacin with Mirabgeron 25 mg a day. All the groups were correctly matched with no confounding variables. The main compartive features noted were the amount of pain relief and the relief from lower urinary tract symptoms among the three groups. Statistical analysis were done by an experienced statistician. RESULTS: Results were tabulated. Table 1 describes descriptive  features of pain. Table 2 depicts statistical differences between 3 groups. Table 3 compares improvement in LUTS among 3 groups.
CONCLUSIONS: Combination of Solifenacin enhanced dose with Mirabgeron gives the best pain relief among all the agents. A combination of Solifenacin with Tamsulosin gives the patient maximum relief from lower urinary tract symptoms.The combination treatments are safe and effectively tolerated. These combinations will go a long way to prevent the misuse of Opioids for post-operative pain relief.
